
## Anders Sonnerborg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6662140/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 1735-1744.	4.0	62
2	Innate lymphoid cell composition associates with COVIDâ€19 disease severity. Clinical and Translational Immunology, 2020, 9, e1224.	3.8	56
3	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	52
4	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	5.8	46
5	All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. Clinical Infectious Diseases, 2021, 72, 2079-2086.	5.8	46
6	Infectivity of SARS-CoV-2: there Is Something More than D614G?. Journal of NeuroImmune Pharmacology, 2020, 15, 574-577.	4.1	44
7	SARSâ€CoVâ€2â€specific humoral and cellular immunity persists through 9 months irrespective of COVIDâ€19 severity at hospitalisation. Clinical and Translational Immunology, 2021, 10, e1306.	3.8	36
8	Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. Pharmaceuticals, 2019, 12, 62.	3.8	30
9	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. Pathogens, 2020, 9, 320.	2.8	26
10	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial. PLoS ONE, 2015, 10, e0122587.	2.5	23
11	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	5.8	16
12	Prophylaxis and treatment of HIV-1 infection in pregnancy – Swedish Recommendations 2017. Infectious Diseases, 2018, 50, 495-506.	2.8	14
13	Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2003, 19, 13-19.	1.1	13
14	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	2.5	8
15	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scandinavian Journal of Infectious Diseases, 2006, 38, 86-103.	1.5	7
16	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Infectious Diseases, 2016, 48, 93-98.	2.8	7
17	Optimal probability weights for estimating causal effects of timeâ€varying treatments with marginal structural Cox models. Statistics in Medicine, 2019, 38, 1891-1902.	1.6	6
18	5th European HIV Drug Resistance Workshop. Future HIV Therapy, 2007, 1, 141-143.	0.4	3

#	Article	IF	CITATIONS
19	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.9	3
20	Incidence, treatment and outcome of HIV-associated hematologic malignancies in people living with HIV in Sweden. AIDS Research and Human Retroviruses, 2021, , .	1.1	1
21	Long-Term Outcome of Liver Transplantation in HIV-1-Positive Patients: 15-Year Follow-Up. ISRN Transplantation, 2013, 2013, 1-8.	0.2	1